Literature DB >> 11158735

Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans.

J Xu1, C Onyewu, H J Yoell, R Y Ali, R J Vilgalys, T G Mitchell.   

Abstract

Infections with the human pathogenic basidiomycetous yeast Cryptococcus neoformans are often treated with fluconazole. Resistance to this antifungal agent has been reported. This study investigated the patterns of mutation to fluconazole resistance in C. neoformans in vitro. The MIC of fluconazole was measured for 21 strains of C. neoformans. The MICs for these 21 strains differed (0.25 to 4.0 microg/ml), but the strains were selected for this study because they exhibited no growth on plates of yeast morphology agar (YMA) containing 8 microg of fluconazole per ml. To determine their mutation rates, six independent cultures from a single original colony were established for each of the 21 strains. Each culture was then spread densely on a YMA plate with 8 microg of fluconazole per ml. A random set of putative mutants was subcultured, and the MIC of fluconazole was determined for each mutant. The 21 strains evinced significant heterogeneity in their mutation rates. The MICs of the putative mutants ranged widely, from their original MIC to 64 microg of fluconazole per ml. However, for this set of 21 strains, there was no significant correlation between the original MIC for a strain and the mutation rate of that strain; the MIC for the mutant could not be predicted from the original MIC. These results suggest that dynamic and heterogeneous mutational processes are involved in generating fluconazole resistance in C. neoformans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158735      PMCID: PMC90307          DOI: 10.1128/AAC.45.2.420-427.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  The hidden danger of primary fluconazole prophylaxis for patients with AIDS.

Authors:  J Berg; C J Clancy; M H Nguyen
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

Review 2.  Rates of spontaneous mutation.

Authors:  J W Drake; B Charlesworth; D Charlesworth; J F Crow
Journal:  Genetics       Date:  1998-04       Impact factor: 4.562

Review 3.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

4.  Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes.

Authors:  S P Franzot; J Mukherjee; R Cherniak; L C Chen; J S Hamdan; A Casadevall
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

5.  Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.

Authors:  M Pfaller; J Zhang; S Messer; M Tumberland; E Mbidde; C Jessup; M Ghannoum
Journal:  Diagn Microbiol Infect Dis       Date:  1998-11       Impact factor: 2.803

6.  Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents.

Authors:  D L Goldman; B C Fries; S P Franzot; L Montella; A Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

7.  Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains.

Authors:  R Franz; S L Kelly; D C Lamb; D E Kelly; M Ruhnke; J Morschhäuser
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

8.  Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994.

Authors:  M E Klepser; M A Pfaller
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

9.  Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR.

Authors:  K A Marr; C N Lyons; T R Rustad; R A Bowden; T C White; T Rustad
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Colony size can be used to determine the MIC of fluconazole for pathogenic yeasts.

Authors:  J Xu; R Vilgalys; T G Mitchell
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

View more
  13 in total

Review 1.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

2.  Geographic distribution of mating type alleles of Cryptococcus neoformans in four areas of the United States.

Authors:  Zhun Yan; Xiaogang Li; Jianping Xu
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Lack of Association between Fluconazole Susceptibility and ERG11 Nucleotide Polymorphisms in Cryptococcus neoformans Clinical Isolates from Uganda.

Authors:  Priscilla Belbir Atim; David B Meya; Elliot S Gerlach; Dennis Muhanguzi; Allan Male; Benedict Kanamwanji; Kirsten Nielsen
Journal:  J Fungi (Basel)       Date:  2022-05-15

4.  Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.

Authors:  T Yamazumi; M A Pfaller; S A Messer; A K Houston; L Boyken; R J Hollis; I Furuta; R N Jones
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

5.  Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.

Authors:  Edward Sionov; Yun C Chang; H Martin Garraffo; Kyung J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2009-05-04       Impact factor: 5.191

6.  Multilocus sequence typing of serially collected isolates of Cryptococcus from HIV-infected patients in South Africa.

Authors:  Marelize Van Wyk; Nelesh P Govender; Thomas G Mitchell; Anastasia P Litvintseva
Journal:  J Clin Microbiol       Date:  2014-03-19       Impact factor: 5.948

Review 7.  A titanic drug resistance threat in Cryptococcus neoformans.

Authors:  Hanna Zafar; Sophie Altamirano; Elizabeth R Ballou; Kirsten Nielsen
Journal:  Curr Opin Microbiol       Date:  2019-11-22       Impact factor: 7.934

8.  Genetic and environmental influences on the germination of basidiospores in the Cryptococcus neoformans species complex.

Authors:  Adrian Forsythe; Aaron Vogan; Jianping Xu
Journal:  Sci Rep       Date:  2016-09-20       Impact factor: 4.379

9.  Mutants with heteroresistance to amphotericin B and fluconazole in Candida.

Authors:  A L R Claudino; R F Peixoto Junior; M S C Melhem; M W Szeszs; J P Lyon; J K Chavasco; M C Franco
Journal:  Braz J Microbiol       Date:  2009-12-01       Impact factor: 2.476

10.  Chromosomal rearrangements between serotype A and D strains in Cryptococcus neoformans.

Authors:  Sheng Sun; Jianping Xu
Journal:  PLoS One       Date:  2009-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.